Mammary Cell News Volume 4.26 | Jul 5 2012

    0
    60

    Mammary Cell News 4.26 July 5, 2012
    Mammary Cell News
         In this issue: Publications | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Mammary Cell News on Twitter

    TOP STORY
    Progestin Suppression of miR-29 Potentiates Dedifferentiation of Breast Cancer Cells via KLF4
    Scientists demonstrated that microRNA-29 (miR-29) directly targets Krüppel-like factor 4 (KLF4), a transcription factor required for the reprogramming of differentiated cells to pluripotent stem cells, and for the maintenance of breast cancer stem cells. [Oncogene] Abstract

    Watch the Video: Isolate Cells In As Little As 25 Minutes with EasySep™

    PUBLICATIONS (Ranked by impact factor of the journal)

    LABORATORY RESEARCH

    Glucose-Regulated Protein 78 Controls Cross-Talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness
    Scientists investigated the potential role of glucose-regulated protein 78 in mediating estrogen resistance. [Cancer Res] Abstract | Press Release

    Junctional Adhesion Molecule-A Is Co-Expressed with HER2 in Breast Tumors and Acts as a Novel Regulator of HER2 Protein Degradation and Signaling
    Researchers aimed to identify if junctional adhesion molecule-A (JAM-A) overexpression was associated with specific subtypes of breast cancer as defined by the expression of human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor. Cross-talk between JAM-A, HER2 and ER was also examined in several breast cell lines, using complementary genetic and pharmacological approaches. [Oncogene] Abstract

    Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells
    Researchers provide preclinical proof of concept that ablating Stat3 signaling in breast cancer cells results in an effective immunotherapy against breast cancer growth and metastasis. [J Immunol] Abstract

    CDK4/6 Inhibition Antagonizes the Cytotoxic Response to Anthracycline Therapy
    Scientists evaluated the efficacy of pharmacological CDK4/6 inhibition in combination with the widely used genotoxic agent doxorubicin in the treatment of triple-negative breast cancer. [Cell Cycle] Abstract

    The Oncoprotein HBXIP Uses Two Pathways to Up-Regulate S100A4 in Promotion of Growth and Migration of Breast Cancer Cells
    Researchers suggest that hepatitis B X-interacting protein (HBXIP) up-regulates S100A4 through activating S100A4 promoter involving STAT4 and inducing PTEN/PI3K/AKT signaling to promote growth and migration of breast cancer cells. [J Biol Chem] Abstract | Full Article

    The Signal Peptide of Mouse Mammary Tumor Virus-Envelope: A Phosphoprotein Tumor Modulator
    To look for cellular functions of p14, different mutants were ectopically expressed in the MCF-7 human breast cancer cell line. Researchers showed that the phosphorylation status of p14 determines whether it functions as a pro-oncogenic or anti-oncogenic modulator. [Mol Cancer Res] Abstract

    The Functional and Structural Characterization of a Novel Oncogene GIG47 Involved in the Breast Tumorigenesis
    Researchers analyzed the expression profile of GIG47 in multiple human cancers including breast cancer and characterized its function related to human carcinogenesis. Based on this oncogenic role of GIG47, they determined the high-resolution structure of GIG47. [BMC Cancer] Abstract | Full Article

    Aromatic-Turmerone Attenuates Invasion and Expression of MMP-9 and COX-2 Through Inhibition of NF-κB Activation in TPA-Induced Breast Cancer Cells
    Scientists investigated the inhibitory effects of aromatic-turmerone on expression and enzymatic activity levels of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced matrix metalloproteinase-9 (MMP-9) and cyclooxygenaase-2 (COX-2) in breast cancer cells. [J Cell Biochem] Abstract

    CLINICAL RESEARCH

    Genetic Variants Associated with Breast Size Also Influence Breast Cancer Risk
    To investigate the genetic factors underlying breast size, researchers conducted a genome-wide association study of self-reported bra cup size, controlling for age, genetic ancestry, breast surgeries, pregnancy history and bra band size, in a cohort of 16,175 women of European ancestry. [BMC Med Genet]
    Abstract | Full Article | Press Release

    DNA Methylation of Circulating DNA: A Marker for Monitoring Efficacy of Neoadjuvant Chemotherapy in Breast Cancer Patients
    Scientists evaluated the potential of methylation changes in circulating DNA to monitor treatment response of breast cancer patients. [Tumour Biol] Abstract

    Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

    INDUSTRY NEWS

    Faculty Husband and Wife Team Developing Math Model to Improve Breast Cancer Detection
    Developing a mathematical model to improve breast cancer detection and save lives has become a personal crusade for two researchers. The couple is currently working to increase the speed of the tests to make them more efficient and more realistic. [Rose-Hulman Institute of Technology] Press Release

    Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia in Breast Cancer Patients Undergoing Chemotherapy
    Teva Pharmaceutical Industries Ltd. announced the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim. [Teva Pharmaceutical Industries Ltd.] Press Release

    Fluxion Biosciences Announces Collaboration with Stanford University School of Medicine for Circulating Tumor Cell Analysis
    Fluxion Biosciences, Inc. announced that it has initiated a collaboration with the Stanford University School of Medicine focused on developing tests to help deliver more effective therapies to cancer patients. [Fluxion Biosciences, Inc.] Press Release

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW 19th Annual International Society for Cellular Therapy (ISCT) Meeting
    April 22-25, 2013
    Auckland, New Zealand

    Visit
    our events page to see a complete list of events in the mammary cell community.

    JOB OPPORTUNITIES

    Research Associate – Chemistry (STEMCELL Technologies, Inc.)

    Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

    Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

    Research Technologist – Media Development (STEMCELL Technologies, Inc.)

    Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


    Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


    Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

    Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)


    Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

    Assistant Professor – Oncology/Breast Cancer (University of Chicago)

    Associate Professor – Metastatic Breast Cancer (University of Colorado Comprehensive Cancer Center)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Mammary Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Mammary Cell News: Archives | Events | Contact Us